Author:
Thakur V.,Anand A. K.,Mukherjee U.,Ghosh D.
Publisher
Springer Science and Business Media LLC
Reference16 articles.
1. Rustin, G.J.S., Nelstrop, A., Stilwel, J. and Lambert, H.E. (1992). Savings obtained by CA125 measurements during therapy for ovarian carcinoma. Eur. J. Cancer. 28, 79–82.
2. Levin, P.T., Knapp, R.C., Malkasian, G., Whitney, C.W., Besek, J.S. and Bast, R.C. (1987). CA 125 for the monitoring of ovarian carcinoma during pretreatment. Obstet. Gynecol. 69, 223–227.
3. Vergote, I.B., Bormen, O.P. and Abeler, V.M. (1987). Elevation of serum CA 125 levels in the monitoring of ovarian cancer. Am. Obstet. Gynecol. 157, 88–92
4. Redman, C.W.E., Black ledge, G.R., Kelly, K., Powell, S., Buxton, E.J. and Lueslay, D.M. (1990). Can early serum CA 125 response predict outcome in epithelial ovarian cancer? Eur. J. Cancer 26, 593–596.
5. Vander Burg, M.E.L., Laumes, F.B., Van Patten, W.L.J. and Stoter, G. (1988). Ovarian cancer, the prognostic value of the serum half life of CA 125 during induction chemotherapy. Gynecol. Oncol. 30, 307–312
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献